Section Arrow
NKTR.NASDAQ
- Nektar Therapeutics
Quotes are at least 15-min delayed:2025/11/19 12:33 EST
Regular Hours
Last
 58.6
-0.57 (-0.96%)
Day High 
61.805 
Prev. Close
59.17 
1-M High
66.92 
Volume 
265.22K 
Bid
58.54
Ask
58.78
Day Low
58.4 
Open
59.17 
1-M Low
52.5 
Market Cap 
1.20B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 56.96 
20-SMA 59.1 
50-SMA 57.39 
52-W High 66.92 
52-W Low 6.48 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-8.64/-9.43
Enterprise Value
1.29B
Balance Sheet
Book Value Per Share
4.18
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
217.72M
Operating Revenue Per Share
4.34
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NUVBNuvation Bio7.28+2.48+51.67%-- 
CYPHCypherpunk Technologies Inc.2.8035-0.1665-5.61%-- 
ASBPAspire Biopharma Holdings Inc.0.0971-0.0086-8.14%-- 
OLMAOlema Pharmaceuticals20.7939+0.6539+3.25%-- 
RXRXRecursion Pharmaceuticals4.0253-0.1347-3.24%-- 
Quotes are at least 15-min delayed:2025/11/19 12:33 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.